Three late-breaking MAPLE-HCM science presentations will be showcased at the HCM Medical Society session on November 7, 2025, including a head-to-head comparison of aficamten versus metoprolol and patient-reported health outcomes.

Moderated poster sessions at the AHA Meetings will cover diastolic function, exercise performance, SEQUOIA-HCM sub-studies on comorbidities and sex-based analyses, and FOREST-HCM insights.

Cytokinetics has announced upcoming November 2025 conference presentations at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions and the American Heart Association Scientific Sessions, both in New Orleans.

The release includes standard forward-looking statements caveat and media contact information.

Cytokinetics emphasizes ongoing development of aficamten, omecamtiv mecarbil, ulacomten, and CK-089, noting these are investigational medicines requiring regulatory approval.

The company reiterates forward-looking statements and provides an about section with a brief overview and its product candidates in development.

Aficamten and other Cytokinetics candidates are stated as investigational and not yet approved by the FDA or other regulators.

The moderated poster session will feature SEQUOIA-HCM-related content.

Event details specify times, session identifiers, locations, and confirm aficamten as investigational during the November 7–10, 2025 timeframe.

Presenters hail from leading institutions including University of Missouri–Kansas City, Columbia University Irving Medical Center, Brigham and Women’s Hospital/Harvard Medical School, Duke University Medical Center, University of Glasgow, and Oregon Health & Science University.

Notable presenters include Michael E. Nassif, Shepard D. Weiner, Andrew Wang, Neal K. Lakdawala, among others from top institutions.

Additional timing and format details cover MAPLE-HCM session times, locations, and whether content is poster or oral.

Poster and imaging abstracts address diastolic function improvements, obesity/diabetes comorbidity sub-studies, and heart failure biomarkers.

Disclaimer notes that the summary is AI-generated and directs readers to the full GlobeNewswire release for complete information.

Aficamten is highlighted as an investigational cardiac myosin inhibitor with positive Phase 3 SEQUOIA-HCM results supporting further development.

FOREST-HCM results will include long-term patient-reported outcome measures with aficamten, presented by Dr. Shepard D. Weiner.

MAPLE-HCM study design compares aficamten to metoprolol in obstructive HCM patients with LVOT obstruction during exercise.